Online ISSN : 1882-2762
ISSN-L : 1882-2762
Original Article
Efficacy and safety of eight-week treatment with astaxanthin in individuals screened for increased oxidative stress burden
Masaaki IwabayashiNoriko FujiokaKeitaro NomotoRyo MiyazakiHozumi TakahashiSawako HibinoYoko TakahashiKoji NishikawaMitsunori NishidaYoshikazu Yonei
Author information

2009 Volume 6 Issue 4 Pages 15-21


Objective: An open-label noncontrolled study was conducted in subjects with increased oxidative stress burden to evaluate the mental and physical effects of antioxidant astaxanthin.
Methods: Of 35 healthy postmenopausal women, 21 with high oxidative stress (diacron-reactive oxygen metabolites; d-ROM) were selected, and 20 (55.7±4.8 years old, BMI 22.1±3.9) were included in the study, after excluding 1 dropout. In subjects orally treated with astaxanthin (Fuji Chemical Industry) at a daily dose of 12 mg for eight weeks, Anti-Aging QOL Common Questionnaire, somatometry, hematological examination/urinalysis, oxidative stress test, and vascular function tests (cardio ankle vascular index, CAVI; ankle brachial pressure index, ABI; fingertip acceleration pulse wave; flow-mediated dilation FMD) were performed before and four and eight weeks after the start of the study.
Results: After eight-week treatment with astaxanthin, significant improvement was observed in 5 of 34 physical symptoms listed in the common questionnaire, including “tired eyes”, “stiff shoulders”, “constipation”, “gray hair”, and “cold skin”, and in 3 of 21 mental symptoms, including “daily life is not enjoyable”, “difficulty in falling asleep”, and “a sense of tension”. In addition, systolic (118.0±16.4 mmHg at baseline, −4.6%, p=0.021) and diastolic blood pressure (74.1±11.7 mmHg at baseline, −6.9%, p‹0.001) significantly decreased. In the vascular function test, CAVI, fingertip acceleration pulse wave, and FMD did not change, but ABI significantly increased from 1.06±0.10 at baseline to 1.10±0.06 at Week 8 (+3.7%, p=0.030). In the oxidative stress test, d-ROM did not change, but BAP significantly increased (+4.6%, p=0.030). In biochemical examination, AST (−19.2%, p=0.044), LDH (−6.4%, p=0.006), and HbA1c (−3.2%, p‹0.001) significantly improved. Although IGF-I and insulin did not change, DHEA-s (−15.1%, p‹0.001), cortisol (−22.8%, p=0.002), and adiponectin (−14.1%, p=0.003) decreased. No serious adverse event occurred during or after the study.
Conclusion: Results show that astaxanthin may enhance antioxidant capacity (increase BAP), reduce lower limb vascular resistance (increase ABI), decrease blood pressure, and improve physical symptoms in women with high oxidative stress.

Content from these authors
© 2009 Japanese Society of Anti-Aging Medicine